JonesResearch initiated coverage of Pharvaris with a Buy rating and $46 price target. The company’s oral deucrictibant has promising efficacy and safety in hereditary angioedema, both as an on-demand therapy for acute attacks and in long-term prophylactic settings, the analyst tells investors in a research note. The firm says deucrictibant’s differentiated profile could drive blockbuster sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Oppenheimer healthcare analysts hold an analyst/industry conference call
- Pharvaris price target raised to $42 from $38 at Oppenheimer
- Pharvaris Reveals Positive HAE Drug Data
- Pharvaris’ deucrictibant shows safety and tolerability in Phase 2 HAE study
- Pharvaris provides business update, expands deucrictibant development program
Questions or Comments about the article? Write to editor@tipranks.com